Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
Bank of America Sees EUR/USD at 1.15 by Year-End 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
Disney Plans TV Restructuring With Hundreds of Layoffs 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Airbus Spain Workers Approve Deal to End Months of Strikes 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ:PETX) securities between March 16, 2015 and February 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/aratana-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
